Applicability of combination with Tirapazamine in boron neutron capture therapy

Japanese Journal of Cancer Research

Volumn 89, Issue 7, 1998, Pages 768-774

  Masunaga, Shin Ichiro ^a   Ono, Koji ^a   Sakurai, Yoshinori ^a   Hori, Hitoshi ^b   Kobayashi, Tooru ^a   Takagaki, Masao ^a   Suzuki, Minoru ^a   Kinashi, Yuko ^a   Akaboshi, Mitsuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Boron neutron capture therapy; dl p boronophenylalanine 10B; Quiescent cell; Sodium borocaptate 10B; Tirapazamine

Indexed keywords

BROXURIDINE; CYTOCHALASIN B; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINESIS; FEMALE; IMMUNOFLUORESCENCE TEST; INTRAPERITONEAL DRUG ADMINISTRATION; MICRONUCLEUS; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR;

EID: 0031693707     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03282.x     Document Type: Article

References (23)

1. Barth, R. F., Soloway, A. H. and Brugger, R. M. Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Cancer Invest., 14, 534-550 (1996).
2. Brown, J. M. and Siim, B. G. Hypoxia-specific cytotoxins in cancer therapy. Semin. Radiat. Oncol. 6, 22-36 (1996).
3. Kennedy, K. A., Teicher, B. A., Rockwell, S. and Sartorelli, A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29, 1-8 (1979).
4. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-1170 (1993).
5. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K. and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242 (1986).
6. Koch, C. J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53, 3992-3997 (1993).
7. Jackson, R. C. The problem of the quiescent cancer cell. Enzyme Regul., 29, 27-46 (1989).
8. Dethlefsen, L. A. In quest of the quaint quiescent cells. In "Radiation Biology in Cancer Research," ed. R. E. Meyn and H. R. Withers, pp. 415-435 (1980). Raven Press, New York.
9. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48, 775-778 (1988).
10. Masunaga, S., Ono, K. and Abe, M. A method for selective measurement of the radiosensitivity of quiescent cells in solid tumors - combination of immunofluorescence staining to BrdU and micronucleus assay. Radiat. Res., 125, 243-247 (1991).
11. Kanda, K. An overview: radiation sources, beam quality, dosimetry and spectroscopy in neutron capture therapy. Strahlenther. Onkol., 165, 67-69 (1989).
12. 10B concentrations and absorbed dose estimations in human malignant melanoma treated by BNCT. Strahlenther. Onkol., 165, 104-106 (1989).
13. Seng, F. and Ley, K. Simple synthesis of 3-amino-1,2,4-benzotriazine-1,4-dioxide. Angew. Chem. Int. Ed. Engl., 11, 1009-1010 (1972).
14. Bremner, J. C. M., Stratford, I. J., Bowler, J. and Adams, G. E. Bioreductive drugs and the selective induction of tumor hypoxia. Br. J. Cancer, 61, 717-721 (1990).
15. Brown, J. M. and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50, 7745-7749 (1990).
16. Ono, K., Wandl, E. O., Tsutsui, K., Sasai, K. and Abe, M. The correlation between cell survival curve and dose response curve of micronucleus (MN) frequency. Strahlenther. Onkol., 165, 824-827 (1989).
17. Fenech, M. and Morley, A. A. Measurement of micronuclei in lymphocytes. Mutat. Res., 147, 29-36 (1985).
18. Ono, K., Masunaga, S., Kinashi, Y., Takagaki, M., Akaboshi, M., Kobayashi, T. and Akuta, K. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys., 34, 1081-1086 (1996).
19. Masunaga, S., Ono, K., Suzuki, M., Takagaki, M., Sakurai, Y., Kobuyashi, T., Akuta, K., Akaboshi, M., Kinashi, Y. and Abe, M. Modification of the response of a quiescent cell population within a solid tumour to boron neutron capture irradiation: studies with nicotinamide and hyperthermia. Br. J. Radiol., 70, 391-398 (1997).
20. Wallen, C. A., Ridinger, D. N. and Dethlefsen, L. A. Heterogeneity of X-ray cytotoxicity in proliferating and quiescent murine mammary carcinoma cells. Cancer Res., 45, 3064-3069 (1985).
21. Shibata, T., Shibamoto, Y., Sasai, K., Oya, N., Takagi, T., Hiraoka, M., Takahashi, M. and Abe, M. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay. Br. J. Cancer, 74 (Suppl. XXVII), S61-S64 (1996).
22. Wheeler, J. A., Stephans, L. C., Tornos, C., Eitel, P. J., Aug, K. K., Milas, L., Allen, P. K. and Meyn, R. E. Jr. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 32, 1487-1493 (1995).
23. Denmeade, S. R., Lin, X. S. and Isaacs, J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28, 251-265 (1996).